Marksans Pharma reported a 9.8% year-on-year increase in consolidated net profit to ₹420.1 crore for the financial year ended March 31, 2026. Revenue from operations rose 12.5% to ₹2,950.9 crore from ₹2,622.8 crore in the previous year. The company achieved its highest-ever total income of approximately ₹3,033 crore, with EBITDA reaching ₹600.8 crore and a margin of 20.4%, surpassing its guidance range of 16–18%.

Key Financial Highlights

The following table summarizes Marksans Pharma's consolidated financial performance for the year ended March 31, 2026:

Operational Performance and Margins

For the quarter ended March 31, 2026, the company reported consolidated revenue of ₹856.1 crore, a 20.8% increase from ₹708.5 crore in the corresponding quarter of the previous year. The consolidated net profit for Q4 FY26 stood at ₹149 crore, compared to ₹90.7 crore in Q4 FY25. The EBITDA for the quarter improved to ₹195.4 crore from ₹126.9 crore in the prior year, reflecting enhanced operational efficiency and cost management. The gross margin for the quarter was 54.4%, while the EBITDA margin stood at 22.8%.

Strategic Developments

During the year, Marksans Pharma incorporated two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada. Additionally, the company implemented the Marksans Employees Stock Option Scheme 2024, granting 400,000 equity stock options to eligible employees. The financial statements were audited by M/s. MSKA & Associates LLP, Statutory Auditors, who issued an unmodified opinion. The Board of Directors has also recommended a final dividend of ₹0.90 per equity share for the financial year 2025-26, subject to shareholder approval.

Management Commentary

Management stated that FY26 was a milestone year, with the company delivering on its guidance and achieving the highest-ever total income of approximately ₹3,033 crore. EBITDA reached ₹600.8 crore with a margin of 20.4%, surpassing the guided range of 16–18%, and PAT hit an all-time high of ₹420.1 crore. Growth was led by new launches across markets, including the Rx branded portfolio in Australia, and a strong recovery in the UK during Q4. The company closed the year with a cash balance of approximately ₹990 crore, maintaining a net cash positive position for over five consecutive years.

Marksans Pharma has granted 3,00,000 stock options to eligible employees under its Marksans Employees Stock Option Scheme 2024. The options, priced at ₹10 each, were approved by the company's Nomination and Remuneration Committee on May 25, 2026. This move follows shareholder approvals passed in September 2024 and August 2025, along with necessary nods from BSE Limited and National Stock Exchange of India Limited in September 2025.

The grant covers 3,00,000 equity shares with a face value of Re. 1 each. The scheme is compliant with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The options will vest one year from the date of grant, following which employees can exercise them within a period of two years.

Key Details of the Grant

The disclosure regarding the ESOP was submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the options are not exercisable immediately and that no money has been realized at this stage.

The meeting to approve the grant commenced at 04:50 p.m. and concluded at 05:25 p.m. on May 25, 2026. Harshavardhan Panigrahi, Company Secretary & Compliance Officer, signed the disclosure on behalf of Marksans Pharma.